Related Experiment Video
Updated: Jun 15, 2026
07:44
Localization of the Locus Coeruleus in the Mouse Brain
Published on: March 7, 2019
Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine
Michael T Heneka1, Fabian Nadrigny, Tommy Regen
1Department of Neurology, Deutsches Zentrum für Neurodegenerative Erkrankungen, University of Bonn, 53105 Bonn, Germany. michael.heneka@ukb.uni-bonn.de
Summary
Norepinephrine (NE) deficiency from locus ceruleus (LC) degeneration worsens Alzheimer's disease (AD) by increasing neuroinflammation and impairing microglial clearance of amyloid-beta (Abeta). Restoring NE levels can improve microglial function in AD.
Area of Science:
- Neuroscience
- Neuroimmunology
- Pharmacology
Background:
- Norepinephrine (NE), supplied by the locus ceruleus (LC), is known to suppress neuroinflammation.
- Alzheimer's disease (AD) is characterized by neuroinflammation and amyloid-beta (Abeta) pathology.
- The role of LC degeneration and subsequent NE deficiency in AD progression remains unclear.
Purpose of the Study:
- To investigate the impact of NE deficiency on microglial functions in the context of AD.
- To determine how LC degeneration affects Abeta deposition and neuroinflammation in a mouse model of AD.
Main Methods:
- NE stimulation of primary mouse microglia to assess effects on cytokine production, migration, and Abeta phagocytosis.
- Induction of LC degeneration in APP-transgenic mice to model NE depletion.
- In vivo laser microscopy to evaluate microglial recruitment and Abeta phagocytosis in NE-depleted mice.
- Administration of L-threo-DOPS, an NE precursor, to assess functional restoration.
Main Results:
- NE stimulation suppressed Abeta-induced inflammatory responses and enhanced microglial migration and Abeta phagocytosis.
- LC degeneration in APP-transgenic mice led to increased inflammatory mediators and elevated Abeta deposition.
- NE-depleted mice exhibited reduced microglial recruitment to Abeta plaques and impaired phagocytosis.
- L-threo-DOPS treatment restored microglial functions in NE-depleted mice.
Conclusions:
- NE deficiency in AD facilitates microglial pro-inflammatory reactions and impairs their ability to clear Abeta.
- LC degeneration contributes to AD pathology by reducing Abeta clearance and exacerbating neuroinflammation.
- Therapeutic strategies targeting microglial phagocytosis in AD should consider the potential impact of NE depletion.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...